Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 226

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 226
---
 Development Expenses

The following table summarizes our research and development expenses (in thousands):

Three Months Ended March 31,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$8,116 $4,370 $3,746 Complementary modulator programs851 2,660 (1,809)Unallocated research and development expenses:Personnel-related (including stock-based compensation)3,187 1,965 1,222 Other R&D related costs986 582 404 Facility, lab and depreciation528 643 (115)Total research and development expenses$13,668 $10,220 $3,448 

(1)NBD1 and combination development program costs include NBD1 stabilizer activities and development of our proprietary combination therapy. Complementary modulator program costs include manufacturing expenses for the modulators.

Research and development expenses increased by $3.4 million to $13.7 million for the three months ended March 31, 2025, from $10.2 million for the three months ended March 31, 2024. The increase in research and development expenses was primarily due to:

•direct research and development expenses increased by $1.9 million primarily due to an increase in clinical programs and combination development activities; and

•unallocated research and development expenses increased by $1.5 million primarily due to a $1.2 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the size of our workforce to support our clinical pipeline. 

19

Table of Contents

General and Administrative Expenses

The following table summarizes our general and administrative expenses (in thousands):

Three Months Ended March 31,Change20252024Personnel-related (including stock-based compensation)$3,523 $1,569 $1,954 Professional services & fees2,037 992 1,045 Facility and depreciation431 366 65 Total general and administrative expenses$5,991 $2,927 $3,064 

General and administrative expenses increased by $3.1 million to $6.0 million for the three months ended March 31, 2025, from $2.9 million for the three months ended March 31, 2024. The increase in general and administrative expenses was primarily due to:

•$2.0 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the